Appln. No. 09/937,375
Amd. dated September 3, 2004
Reply to Office Action of June 3, 2004

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:
Listing of Claims:

Claims 1-7 (Cancelled).

8. (Currently Amended) A composition for gene therapy used for treating a disease susceptible to gene therapy, which contains as active ingredients:

(1) an effective amount of a retrovirus functional substance having an affinity for a virus that contains a gene useful for gene therapy;

(2) and an effective amount of a another functional substance having an affinity specific for a target cell for which transfer of the gene is required heparin-II-binding domain of fibronectin; and

(3) an effective amount of vascular endothelial cells.

Claims 9-41 (Cancelled).

42. (Currently Amended) The composition according to any one of claims 1 to 13 claim 8, wherein a protein encoded by the gene useful for gene therapy transferred gene is a therapeutic protein which is expressed upon expression of

Appln. No. 09/937,375 Amd. dated September 3, 2004 Reply to Office Action of June 3, 2004

the gene in the target cell in an amount sufficient for the treatment.

43. (Previously Presented) The composition according to claim 42, wherein the protein is an enzyme or a cytokine.

Claims 44-50 (Cancelled).